Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial - PubMed (original) (raw)
Clinical Trial
. 2012 Aug 25;380(9843):738-46.
doi: 10.1016/S0140-6736(12)60642-4. Epub 2012 Jun 29.
Affiliations
- PMID: 22748702
- DOI: 10.1016/S0140-6736(12)60642-4
Clinical Trial
Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial
Kim Papp et al. Lancet. 2012.
Abstract
Background: Apremilast, a small-molecule inhibitor of phosphodiesterase 4, works intracellularly to modulate proinflammatory and anti-inflammatory mediator production, and doses of 20 mg twice daily have shown efficacy in the treatment of moderate to severe plaque psoriasis in a 12-week phase 2 study. We assessed the clinical efficacy and safety of different doses of apremilast in the treatment of patients with moderate to severe plaque psoriasis.
Methods: In this phase 2b, multicentre, randomised, placebo-controlled, dose-ranging study, patients (aged ≥18 years) with moderate to severe psoriasis were randomly assigned (in a 1:1:1:1 ratio) to receive oral placebo or apremilast 10, 20, or 30 mg twice daily at 35 US and Canadian sites between Sept 24, 2008, and Oct 21, 2009. At week 16, patients in the placebo group were assigned apremilast 20 or 30 mg twice daily until week 24. Randomisation was generated with a permuted-block randomisation list via interactive voice response system. For the first 16 weeks, treatment assignment was concealed from both investigators and participants. During weeks 16-24, investigators and participants all knew that treatment was active, but the dose was concealed. The primary endpoint was the proportion of patients achieving at least 75% reduction from baseline psoriasis area and severity index (PASI-75) at week 16. Analyses were by intention to treat; missing values were imputed by last-observation-carried-forward. This trial is registered with ClinicalTrials.gov, number NCT00773734.
Findings: 89 patients were randomly assigned apremilast 10 mg, 87 apremilast 20 mg, and 88 apremilast 30 mg twice daily; 88 were assigned placebo. At week 16, PASI-75 was achieved in five patients (6%) assigned placebo, ten (11%) assigned apremilast 10 mg, 25 (29%) assigned 20 mg, and 36 (41%) assigned 30 mg. Apremilast 10 mg did not differ significantly from placebo in achievement of the endpoint (odds ratio 2·10; 95% CI 0·69-6·42); for both apremilast 20 mg (6·69; 2·43-18·5; p<0·0001) and apremilast 30 mg (11·5; 4·24-31·2; p<0·0001), the differences from placebo were significant. Most adverse events (96%) were mild or moderate; at least 5% of patients had nausea, upper respiratory tract infection, diarrhoea, nasopharyngitis, headache, arthralgia (placebo), gastroenteritis, or dyspepsia. Eight serious adverse events occurred (three each, placebo and apremilast 20 mg; two, apremilast 30 mg); none were judged to be related to apremilast. Apremilast had no apparent effect on the results of haematological, urinalysis, immunological or inflammation, serum chemistry, or electrocardiographic tests.
Interpretation: Apremilast, given orally at 20 or 30 mg twice daily, seems to be efficacious, safe, and tolerable for patients with moderate to severe plaque psoriasis. Our results support continuing, longer-term studies.
Funding: Celgene Corporation.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
- Apremilast: a step forward in the treatment of psoriasis?
van de Kerkhof PC. van de Kerkhof PC. Lancet. 2012 Aug 25;380(9843):708-9. doi: 10.1016/S0140-6736(12)60896-4. Epub 2012 Jun 29. Lancet. 2012. PMID: 22748703 No abstract available.
Similar articles
- Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).
Paul C, Cather J, Gooderham M, Poulin Y, Mrowietz U, Ferrandiz C, Crowley J, Hu C, Stevens RM, Shah K, Day RM, Girolomoni G, Gottlieb AB. Paul C, et al. Br J Dermatol. 2015 Dec;173(6):1387-99. doi: 10.1111/bjd.14164. Epub 2015 Nov 7. Br J Dermatol. 2015. PMID: 26357944 Clinical Trial. - Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial.
Bachelez H, van de Kerkhof PC, Strohal R, Kubanov A, Valenzuela F, Lee JH, Yakusevich V, Chimenti S, Papacharalambous J, Proulx J, Gupta P, Tan H, Tawadrous M, Valdez H, Wolk R; OPT Compare Investigators. Bachelez H, et al. Lancet. 2015 Aug 8;386(9993):552-61. doi: 10.1016/S0140-6736(14)62113-9. Epub 2015 Jun 4. Lancet. 2015. PMID: 26051365 Clinical Trial. - Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study.
Papp KA, Kaufmann R, Thaçi D, Hu C, Sutherland D, Rohane P. Papp KA, et al. J Eur Acad Dermatol Venereol. 2013 Mar;27(3):e376-83. doi: 10.1111/j.1468-3083.2012.04716.x. Epub 2012 Oct 3. J Eur Acad Dermatol Venereol. 2013. PMID: 23030767 Clinical Trial. - Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Deeks ED. Deeks ED. Drugs. 2015 Aug;75(12):1393-403. doi: 10.1007/s40265-015-0439-1. Drugs. 2015. PMID: 26220911 Review. - Apremilast: A Review in Psoriasis and Psoriatic Arthritis.
Keating GM. Keating GM. Drugs. 2017 Mar;77(4):459-472. doi: 10.1007/s40265-017-0709-1. Drugs. 2017. PMID: 28213862 Review.
Cited by
- Tyrosine Kinase 2 Inhibition With Zasocitinib (TAK-279) in Psoriasis: A Randomized Clinical Trial.
Armstrong AW, Gooderham M, Lynde C, Maari C, Forman S, Green L, Laquer V, Zhang X, Franchimont N, Gangolli EA, Blau J, Zhao Y, Zhang W, Srivastava B, Heap G, Papp K. Armstrong AW, et al. JAMA Dermatol. 2024 Oct 1;160(10):1066-1074. doi: 10.1001/jamadermatol.2024.2701. JAMA Dermatol. 2024. PMID: 39167366 Free PMC article. Clinical Trial. - Pharmacokinetics and Bioequivalence of Apremilast Tablets in Chinese Healthy Subjects Under Fasting and Postprandial States.
Bai W, Sun X, Qiu B, Guo C, Song H, Hu Y, Zhang X, Yin P, Wang X, Dong Z. Bai W, et al. Drug Des Devel Ther. 2024 Jun 14;18:2273-2285. doi: 10.2147/DDDT.S461771. eCollection 2024. Drug Des Devel Ther. 2024. PMID: 38895175 Free PMC article. Clinical Trial. - Safety and effectiveness of apremilast in Japanese patients with psoriatic disease: Results of a post-marketing surveillance study.
Ohtsuki M, Okubo Y, Saeki H, Igarashi A, Imafuku S, Abe M, Chaudhari S, Yaguchi M, Emoto A, Morita A. Ohtsuki M, et al. J Dermatol. 2024 Jul;51(7):950-963. doi: 10.1111/1346-8138.17270. Epub 2024 May 22. J Dermatol. 2024. PMID: 38775204 Free PMC article. - Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
Crowley EL, Gooderham MJ. Crowley EL, et al. Pharmaceutics. 2023 Dec 22;16(1):23. doi: 10.3390/pharmaceutics16010023. Pharmaceutics. 2023. PMID: 38258034 Free PMC article. Review. - A comprehensive overview of psoriatic research over the past 20 years: machine learning-based bibliometric analysis.
Yu C, Huang Y, Yan W, Jiang X. Yu C, et al. Front Immunol. 2023 Oct 26;14:1272080. doi: 10.3389/fimmu.2023.1272080. eCollection 2023. Front Immunol. 2023. PMID: 37954610 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical